Get all your news in one place.
100's of premium titles.
One app.
Start reading
Evening Standard
Evening Standard
Alex Daniel

GSK sales hampered by slump in demand for key vaccine

Shares in GSK fell after it cut its outlook for its annual vaccines sales (PA) - (PA Wire)

Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth.

Sales of the jab for respiratory syncytial virus (RSV), previously a key driver of vaccine sales which saw an extremely successful launch last year, plunged 72% year-on-year to £188 million, hit by fewer of the shots being given out in the US.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.